Lupin acquires injectables firm I'rom Pharmaceuticals in Japan
This article was originally published in Scrip
Executive Summary
Lupin continues to make niche buys internationally, this time acquiring the Toyko-based specialty injectables firm, I’rom Pharmaceutical Co, for an undisclosed sum.
You may also be interested in...
Lupin Rationalizes Japan Operations, Sheds Injectables Business
Lupin sells Japanese injectables business, eight years after it made an acquisition in that segment there. The Indian firm now plans to concentrate on building a hybrid pharma model in the country.
Lupin Rationalizes Japan Operations, Sheds Injectables Business
Lupin sells Japanese injectables business, eight years after it made an acquisition in that segment there. The Indian firm now plans to concentrate on building a hybrid pharma model in the country.
India IPR Realities: Pharma, Legal Heads Discuss Winds Of Change, ‘Damocles Sword’
Leaders from Novartis, Bayer, Sun Pharma, the Indian Pharmaceutical Alliance, Médecins Sans Frontières and Anand and Anand discuss India’s evolving intellectual property rights landscape, including pre-grant oppositions, enforcement action and other realities. Concerns around evergreening, restrictions on patent-eligible subject matter and compulsory licensing were also key talking points at a recent conference in Hyderabad.